Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 6, 2022
June 6, 2022
February 15, 2024
February 9, 2024
January 19, 2024
January 16, 2024